Novartis AG has announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, related to its tender offer to acquire all outstanding shares of Regulus Therapeutics Inc. The expiration of this waiting period, which occurred at 11:59 p.m. on June 20, 2025, is a crucial step towards the completion of the transaction. Under the agreement, Novartis will offer $7.00 in cash per share of Regulus, along with a contingent value right for a potential additional payment of $7.00 in cash, contingent on the achievement of a regulatory milestone. The tender offer is set to expire one minute past 11:59 p.m. on June 24, 2025, unless extended or terminated earlier.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novartis AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001114133-en) on June 23, 2025, and is solely responsible for the information contained therein.